WO2000035910A1 - Derivative of paroxetine - Google Patents
Derivative of paroxetine Download PDFInfo
- Publication number
- WO2000035910A1 WO2000035910A1 PCT/GB1999/004176 GB9904176W WO0035910A1 WO 2000035910 A1 WO2000035910 A1 WO 2000035910A1 GB 9904176 W GB9904176 W GB 9904176W WO 0035910 A1 WO0035910 A1 WO 0035910A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- paroxetine
- salt
- acid
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
- the present invention relates to a novel derivative of paroxetine.
- This invention relates to a novel derivative of paroxetine.
- the compound of this invention may exist in the free acid form as shown in formula (1) or as the corresponding zwitterion. Both forms are part of this invention.
- the compound of formula (1) may also exist as salts for example with alkali metals or amines, or addition salts with strong acids. Suitable salts include those with alkali metals, preferably sodium, potassium or lithium, or with a mineral acid, for example hydrochloric acid, or sulphonic acid. Amine salts may include salts with paroxetine itself. Also the compound of formula (1) may exist as a mono- or di-salt, or as a mixed salt.
- a particularly important salt is the 1 :1 (by mole) salt with paroxetine.
- Compounds of structure (1) have a chiral centre on the piperidine nitrogen substituent as well as the two chiral centres on the piperidine ring, so may exist in two forms. These forms may be separated by crystallisation or chromatography, optionally in the form of a salt, for example a salt with an optically active base.
- the present invention also provides a method for the preparation of compounds of formula (1) by the addition reaction of paroxetine (as the free base) to maleic acid.
- the procedure may be carried out at elevated temperature in an appropriate solvent.
- solvents suitable for the addition reaction are polar aprotic solvents, for example N.N-dimethylformamide, alcohols such as ethanol and isopropanol, and esters such as ethyl acetate, and hydrocarbons such as toluene.
- polar aprotic solvents for example N.N-dimethylformamide
- alcohols such as ethanol and isopropanol
- esters such as ethyl acetate
- hydrocarbons such as toluene.
- the reaction of paroxetine with maleic acid tends to result in the recovery of the paroxetine salt of the compound of formula (1) rather than the free acid. Accordingly the free acid is suitably obtained by preparing the salt and treating the salt to recover the acid.
- the paroxetine salt of compound (1) may conveniently be prepared by contacting paroxetine free base with maleic acid in a suitable solvent, for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
- a suitable solvent for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
- the paroxetine salt of compound (1) may be isolated by crystallisation, and may be purified by a hot slurry, for example at reflux temperature in an appropriate solvent, for example an ester such as ethyl acetate, an alcohol such as propan-2-ol, or a ketone such as acetone.
- the paroxetine salt of compound (1) may also be prepared from paroxetine maleate (1 :1) salt by heating in an appropriate solvent, preferably butan-2-ol.
- Compound (1) may be isolated from its paroxetine salt by acidification with 1 equivalent of acid, for example hydrochloric acid.
- compound (1) may be prepared by addition of 1 molar equivalent of hydrogen chloride in propan-2-ol to a suspension of the paroxetine salt of compound (1) in propan-2-ol with or without heating, and isolated as the free acid by crystallisation from the reaction medium by the addition of water and acetone.
- compound (1) free acid may be prepared from the isolated paroxetine salt by treatment with 1 equivalent of hydrochloric acid in acetone followed by crystallisation from the medium.
- salts of compound (1) for example mono sodium or mono lithium salts may be prepared by reaction of compound (1) with 1 equivalent of base, for example sodium or lithium hydroxide respectively.
- Another class of salts of compound (1) may be formed by reaction with 2 equivalents of strong base, such as for example the disodium or dipotassium salt.
- Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Maleic acid is commercially available.
- Compound (1) and its salts of this invention are anticipated to be useful to treat and prevent the following disorders:
- the Disorders are hereinafter referred to as "the Disorders”.
- the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a compound of the invention to a sufferer in need thereof.
- the present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises an admixture of a compound of the invention with a pharmaceutically acceptable carrier.
- the present invention also provides the use of a compound of the invention for treating and/or preventing any one or more of the Disorders.
- the present invention also provides the use of a compound of the invention in the manufacture of a medicament for treating and/or preventing any one or more of the Disorders.
- the present invention is applied to the treatment of depression, OCD and panic.
- compositions containing a compound of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine derivative or salt.
- the medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
- the composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
- Preferred unit dosage forms include tablets or capsules.
- compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
- Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilised in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
- compositions include those described EP-B-0223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
- paroxetine base and maleic acid 0.5 mole equivalents
- ethyl acetate 5 volumes
- the crystalline solid which formed was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1 -N-(3S,4R)- trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid as the paroxetine salt.
- N-phenyloxycarbonyl paroxetine (5.0 kg ), potassium hydroxide flake (4.5 kg ) and toluene (75.0 litres) were heated to reflux under a nitrogen atmosphere. After stirring for 4 hours at reflux the contents of the reactor were allowed to cool to room temperature. Water (50 litres) was added and the mixture stirred for 30 minutes and then allowed to settle. The lower aqueous layer was drained from the reactor and the toluene layer heated to reflux and dried in a Dean and Stark apparatus. Toluene (10 litres) was added and approximately 10 litres of the solvent was removed by distillation. The remaining solution was cooled to approximately 90-95°C and solid maleic acid (1.04 kg) was added with vigorous stirring.
- IR ⁇ maxcm 1 ) 1608, 1512, 1376, 1298, 1234, 1181, 1143, 1106, 1033, 930, 831,
- Example 4 Preparation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU17888/00A AU1788800A (en) | 1998-12-11 | 1999-12-10 | Derivative of paroxetine |
EP99961195A EP1137646A1 (en) | 1998-12-11 | 1999-12-10 | Derivative of paroxetine |
JP2000588170A JP2002532494A (en) | 1998-12-11 | 1999-12-10 | Derivatives of paroxetine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9827431.9 | 1998-12-11 | ||
GBGB9827431.9A GB9827431D0 (en) | 1998-12-11 | 1998-12-11 | Novel compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000035910A1 true WO2000035910A1 (en) | 2000-06-22 |
Family
ID=10844142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/004176 WO2000035910A1 (en) | 1998-12-11 | 1999-12-10 | Derivative of paroxetine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1137646A1 (en) |
JP (1) | JP2002532494A (en) |
AU (1) | AU1788800A (en) |
GB (1) | GB9827431D0 (en) |
WO (1) | WO2000035910A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479525B2 (en) | 2000-12-29 | 2002-11-12 | Synthon Bv | Aspartate derivative of amlodipine |
US6518288B2 (en) | 2000-12-29 | 2003-02-11 | Synthon Bv | Amlodipine fumarate |
US6538012B2 (en) | 2000-12-29 | 2003-03-25 | Synthon Bv | Amlodipine hemimaleate |
US6600047B2 (en) | 2000-12-29 | 2003-07-29 | Synthon Bv | Process for making amlodipine maleate |
US6602893B2 (en) | 2000-12-29 | 2003-08-05 | Synthon Bv | Amide derivative of amlodipine |
US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
US6830933B2 (en) | 2000-12-29 | 2004-12-14 | Synthon Bv | Reference standards for determining the purity or stability of amlodipine maleate and processes therefor |
US6919087B2 (en) | 2000-12-29 | 2005-07-19 | Synthon Bv | Pharmaceutical compositions comprising amlodipine maleate |
US7199247B2 (en) | 2000-12-29 | 2007-04-03 | Synthon Ip Inc. | Amide derivative of amlodipine |
US7335380B2 (en) | 2000-12-29 | 2008-02-26 | Synthon Ip Inc. | Amlodipine free base |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0188081A2 (en) * | 1984-12-04 | 1986-07-23 | Novo Nordisk A/S | Use of paroxetine for the manufacture of a medicament for the treatment of obesity |
WO1998056787A1 (en) * | 1997-06-10 | 1998-12-17 | Synthon B.V. | 4-Phenylpiperidine compounds |
WO1999040084A1 (en) * | 1998-02-06 | 1999-08-12 | Smithkline Beecham Plc | Salts of paroxetine |
WO1999052901A1 (en) * | 1998-04-09 | 1999-10-21 | Smithkline Beecham Plc | Paroxetine maleate |
-
1998
- 1998-12-11 GB GBGB9827431.9A patent/GB9827431D0/en not_active Ceased
-
1999
- 1999-12-10 AU AU17888/00A patent/AU1788800A/en not_active Abandoned
- 1999-12-10 EP EP99961195A patent/EP1137646A1/en not_active Withdrawn
- 1999-12-10 JP JP2000588170A patent/JP2002532494A/en active Pending
- 1999-12-10 WO PCT/GB1999/004176 patent/WO2000035910A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0188081A2 (en) * | 1984-12-04 | 1986-07-23 | Novo Nordisk A/S | Use of paroxetine for the manufacture of a medicament for the treatment of obesity |
WO1998056787A1 (en) * | 1997-06-10 | 1998-12-17 | Synthon B.V. | 4-Phenylpiperidine compounds |
WO1999040084A1 (en) * | 1998-02-06 | 1999-08-12 | Smithkline Beecham Plc | Salts of paroxetine |
WO1999052901A1 (en) * | 1998-04-09 | 1999-10-21 | Smithkline Beecham Plc | Paroxetine maleate |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 87, no. 17, 24 October 1977, Columbus, Ohio, US; abstract no. 127707, PETERSEN, ERLING N. ET AL: "Effects of 5HT uptake inhibitors on the pressor response to 5HT in the pithed rat. The significance of the 5HT blocking property" XP002129319 * |
EUR. J. PHARMACOL. (1977), 43(3), 209-15 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479525B2 (en) | 2000-12-29 | 2002-11-12 | Synthon Bv | Aspartate derivative of amlodipine |
US6518288B2 (en) | 2000-12-29 | 2003-02-11 | Synthon Bv | Amlodipine fumarate |
US6538012B2 (en) | 2000-12-29 | 2003-03-25 | Synthon Bv | Amlodipine hemimaleate |
US6600047B2 (en) | 2000-12-29 | 2003-07-29 | Synthon Bv | Process for making amlodipine maleate |
US6602893B2 (en) | 2000-12-29 | 2003-08-05 | Synthon Bv | Amide derivative of amlodipine |
US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
US6830933B2 (en) | 2000-12-29 | 2004-12-14 | Synthon Bv | Reference standards for determining the purity or stability of amlodipine maleate and processes therefor |
US6919087B2 (en) | 2000-12-29 | 2005-07-19 | Synthon Bv | Pharmaceutical compositions comprising amlodipine maleate |
US7115638B2 (en) | 2000-12-29 | 2006-10-03 | Synthon Ip Inc. | Amide derivative of amlodipine |
US7199247B2 (en) | 2000-12-29 | 2007-04-03 | Synthon Ip Inc. | Amide derivative of amlodipine |
US7335380B2 (en) | 2000-12-29 | 2008-02-26 | Synthon Ip Inc. | Amlodipine free base |
Also Published As
Publication number | Publication date |
---|---|
EP1137646A1 (en) | 2001-10-04 |
GB9827431D0 (en) | 1999-02-03 |
JP2002532494A (en) | 2002-10-02 |
AU1788800A (en) | 2000-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2782517A1 (en) | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | |
EP1078925A1 (en) | 4-Phenylpiperidine compounds | |
EP0674514A1 (en) | Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives | |
EP1137646A1 (en) | Derivative of paroxetine | |
WO2000035873A1 (en) | Process for preparation of paroxetine maleate | |
CA2164296C (en) | Heterocyclic chemistry | |
EP2072510A1 (en) | Crystalline form of azelastine | |
SK13622000A3 (en) | Crystalline form of paroxetine | |
WO2000032595A1 (en) | Process for the production of paroxetine hydrochloride acetone solvate | |
US20020137938A1 (en) | Novel process | |
WO2001014335A1 (en) | Process for preparation of paroxetin intermediate | |
WO2001012623A1 (en) | Process for the preparation of paroxetine hydrochloride | |
WO2000032592A1 (en) | Process for the preparation of paroxetine hydrochloride | |
WO2001025201A1 (en) | Process for the preparation of paroxetin intermediate | |
WO2000039121A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
WO2000078752A1 (en) | Process for the production of paroxetine hydrochloride | |
US20010008940A1 (en) | Novel process | |
JP3113447B2 (en) | Aminocarboxylic acid derivatives, their production and use | |
EP1140911A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
WO2000032596A1 (en) | Amine salts of paroxetine | |
WO2001017966A1 (en) | Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine | |
WO2001025202A1 (en) | Process for the preparation of paroxetine intermediate | |
WO2001002357A2 (en) | Process for the synthesis of 4-(4'-fluorophenyl)-piperidines | |
EP1140912A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
CZ20003343A3 (en) | Crystalline form of paroxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17888 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 588170 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999961195 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09857637 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999961195 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999961195 Country of ref document: EP |